![PDF) Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application PDF) Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application](https://i1.rgstatic.net/publication/328770510_Levosimendan_in_Acute_and_Advanced_Heart_Failure_an_Expert_Perspective_on_Posology_and_Therapeutic_Application/links/5fbcfee4299bf104cf6f777d/largepreview.png)
PDF) Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application
![Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey | International Journal of Gynecologic Cancer Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/sites/default/files/highwire/ijgc/31/10.cover-source.jpg)
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey | International Journal of Gynecologic Cancer
![Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice | Request PDF Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice | Request PDF](https://i1.rgstatic.net/publication/333646161_Identification_of_predictive_factors_for_overall_survival_at_baseline_and_during_azacitidine_treatment_in_high-risk_myelodysplastic_syndrome_patients_treated_in_the_clinical_practice/links/5fb718b292851c933f42a737/largepreview.png)
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice | Request PDF
![Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection - European Urology Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/169d2b4a-1f53-4c42-afe9-718692dcf82c/gr1.jpg)
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection - European Urology
![PDF) Extracorporeal shock-wave therapy for supraspinatus calcifying tendinitis: a randomized clinical trial comparing two different energy levels | Angelo Cacchio - Academia.edu PDF) Extracorporeal shock-wave therapy for supraspinatus calcifying tendinitis: a randomized clinical trial comparing two different energy levels | Angelo Cacchio - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/50189910/mini_magick20190129-31835-7r2dsq.png?1548807514)
PDF) Extracorporeal shock-wave therapy for supraspinatus calcifying tendinitis: a randomized clinical trial comparing two different energy levels | Angelo Cacchio - Academia.edu
![Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - Journal of Allergy and Clinical Immunology Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - Journal of Allergy and Clinical Immunology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/bb1c35eb-e1aa-45b8-a000-40a3f99c2e59/fx1.jpg)
Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - Journal of Allergy and Clinical Immunology
![Come migliorare la ricerca clinica: l'epoca del fare. Resoconto dell'evento annuale di AICRO - Seconda parte | CRAsecrets.com Come migliorare la ricerca clinica: l'epoca del fare. Resoconto dell'evento annuale di AICRO - Seconda parte | CRAsecrets.com](https://i0.wp.com/crasecrets.com/wp-content/uploads/2017/12/working-group-300x199.png?resize=300%2C199)
Come migliorare la ricerca clinica: l'epoca del fare. Resoconto dell'evento annuale di AICRO - Seconda parte | CRAsecrets.com
![A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study | British Journal of Cancer A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6602241/MediaObjects/41416_2004_Article_BF6602241_Fig1_HTML.gif)
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study | British Journal of Cancer
![Il Clinical Trial Center del Gemelli illustra i percorsi della ricerca ai Pazienti Esperti - Policlinico Universitario A. Gemelli IRCCS Il Clinical Trial Center del Gemelli illustra i percorsi della ricerca ai Pazienti Esperti - Policlinico Universitario A. Gemelli IRCCS](https://www.policlinicogemelli.it/wp-content/uploads-shared/2022/01/LogoCTC_News.jpg)
Il Clinical Trial Center del Gemelli illustra i percorsi della ricerca ai Pazienti Esperti - Policlinico Universitario A. Gemelli IRCCS
![TCT-474 FANTOM II Long Lesion Study: Initial Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions—First Report: 2-Year Outcomes | Journal of the American College of Cardiology TCT-474 FANTOM II Long Lesion Study: Initial Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions—First Report: 2-Year Outcomes | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/6585107f-954d-4641-b6e6-9bb4ea022338/j.jacc.2021.09.1327.fp.png)
TCT-474 FANTOM II Long Lesion Study: Initial Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions—First Report: 2-Year Outcomes | Journal of the American College of Cardiology
![PDF) Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond PDF) Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond](https://i1.rgstatic.net/publication/355139239_Evolution_of_Clinical_Trials_in_Ovarian_Cancer_Management_over_the_Past_20_Years_Never_Settle_Down_Always_Go_Beyond/links/615fa0f71eb5da761e5dfc84/largepreview.png)
PDF) Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond
![PDF) Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond | elena giudice - Academia.edu PDF) Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond | elena giudice - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/81852954/mini_magick20220307-9217-1oxqmho.png?1646681506)
PDF) Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond | elena giudice - Academia.edu
![Infrarenal Abdominal Aortic Aneurysm Endovascular Treatment: Long-term Results From a Single-Center Experience in an Unselected Patient Population - Annals of Vascular Surgery Infrarenal Abdominal Aortic Aneurysm Endovascular Treatment: Long-term Results From a Single-Center Experience in an Unselected Patient Population - Annals of Vascular Surgery](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/7e6907f9-0727-416f-ae9d-f0b7e3b5368d/gr1.jpg)
Infrarenal Abdominal Aortic Aneurysm Endovascular Treatment: Long-term Results From a Single-Center Experience in an Unselected Patient Population - Annals of Vascular Surgery
![Plasmatic Exosome Number and Size Distinguish Prostate Cancer Patients From Healthy Individuals: A Prospective Clinical Study | Oncology - Frontiers Plasmatic Exosome Number and Size Distinguish Prostate Cancer Patients From Healthy Individuals: A Prospective Clinical Study | Oncology - Frontiers](https://www.frontiersin.org/files/MyHome%20Article%20Library/727317/727317_Thumb_400.jpg)